Potential drug-drug interactions within Veterans Affairs medical centers

American Journal of Health-System Pharmacy

Volumn 64, Issue 14, 2007, Pages 1500-1505

  Mahmood, Maysaa ^a   Malone, Daniel C ^a   Skrepnek, Grant H ^a   Abarca, Jacob ^b   Armstrong, Edward P ^c   Murphy, John E ^c   Grizzle, Amy J ^c   Ko, Yu ^c   Woosley, Raymond L ^d,e  

^a UNIVERSITY OF ARIZONA   (United States)

^b Wellpoint Inc   (United States)

^c Department of Pharmacy Practice   (United States)

^d C Path Institute   (United States)

^e Cleveland Clinic Lerner   (United States)

Author keywords

Anticoagulants; Antidepressants; Antiinflammatory agents; Antiretroviral agents; Antivirals; Drug interactions; Ganciclovir; Monoamine oxidase inhibitors; Pharmacokinetics; Prescriptions; Sulfinpyrazone; Thyroid drugs; Uricosuric agents; Warfarin; Zidovudine

Indexed keywords

ALKALOID; ALLOPURINOL; ANTICOAGULANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; ERGOT ALKALOID; FIBRIC ACID DERIVATIVE; GANCICLOVIR; MACROLIDE; METHOTREXATE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PIMOZIDE; PYRROLE DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAMYCIN; SEROTONIN UPTAKE INHIBITOR; SULFINPYRAZONE; THEOPHYLLINE DERIVATIVE; THYROID HORMONE; TRIMETHOPRIM; UNINDEXED DRUG; WARFARIN; ZIDOVUDINE;

AMBULATORY CARE; ARTICLE; AUTONOMIC DYSFUNCTION; BLEEDING; COGNITION; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; HUMAN; MEDICATION ERROR; NEUROMUSCULAR FUNCTION; OUTPATIENT; PHARMACY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SEROTONIN SYNDROME; SIDE EFFECT;

EID: 34447545865     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060548     Document Type: Article

References (44)

1. Kohn LT, Corrigan JM, Donaldson MS, eds. To err is human: building a safer health system. Washington, DC: National Academy Press; 1999.
2. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997; 277:307-11.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200-5.
4. Leape LL, Bates DW, Cullen DJ et al. Systems analysis of adverse drug events. JAMA. 1995; 274:35-43.
5. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995; 155:1949-56.
6. Thomas A, Routledge PA. Drug interactions in clinical practice. Focus - Pharmacovigillance Bull. 2003:1-7.
7. Preskorn SH, Silkey B, Saha R et al. Complexity in medication use in the Veterans Affairs Healthcare System: part I: outpatient use in relation to age and number of prescribes. J Psychiatr Pract. 2005; 11:5-15.
8. Bjerrum L, Andersen M, Petersen G et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 2003; 21:153-6.
9. Goldberg RM, Mabee J, Chan L et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996; 14:447-50.
10. Herr RD, Caravati EM, Tyler LS et al. Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med. 1992; 21:1331-6.
11. May JR, DiPiro JT, Sisley JF. Drug interactions in surgical patients. Am J Surg. 1987; 153:327-35.
12. Morera T, Gervasini G, Carrillo JA et al. Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting. Ann Pharmacother. 2004; 38:1301-6.
13. Kaufman DW, Kelly JP, Rosenberg L et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 287:337-44.
14. Preskorn SH. How drug-drug interactions can impact managed care. Am J Manag Care. 2004; 10:S186-98.
15. Malone DC, Hutchins DS, Haupert H et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health-Syst Pharm. 2005; 62:1983-91.
16. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet. 1998; 351:643-4.
17. Bergk V, Gasse C, Rothenbacher D et al. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther. 2004; 76:85-96.
18. Jankel C, Speedie S. Detecting drug interactions: a review of the literature. Ann Pharmacother. 1990; 24:982-9.
19. Bjorkman I, Fastbom J, Schmidt I et al. Drug-drug interactions in the elderly. Ann Pharmacother. 2002; 36:1675-81.
20. Halkin H, Katzir I, Kurman I et al. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther. 2001; 69:260-5.
21. Peng CC, Glassman PA, Marks IR et al. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm. 2003; 9:513-22.
22. Smith MW, Joseph GJ. Pharmacy data in the VA health care system. Med Care Res Rev. 2003; 60(3 suppl):92S-123S.
23. Malone DC, Abarca J, Hansten PD et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc. 2004; 44:142-51.
24. Becker ML, Kallewaurd M, Caspers PW et al. Potential determinant of drug-drug interactions associated dispensing in community pharmacies. Drug Saf. 2005; 28:371-8.
25. Fulda TR, Lyles A, Pugh MC et al. Current status of prospective drug utilization review. J Manag Care Pharm. 2004; 10:433-41.
26. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352:1112-20.
27. Preskorn SH. Drug-drug interactions: proof of relevance. Part I. J Psychiatr Pract. 2005; 11:116-22.
28. Birmes P, Coppin D, Schmitt L et al. Serotonin syndrome: a brief review. CMAJ. 2003; 168:1439-42.
29. Grosset KA, Grosset DG. Prescribed drugs and neurological complications. J Neurol Neurosurg Psychiatry. 2004; 75:iii,2-8.
30. Tetrud JW, Koller WC. A novel formulation of selegiline for the treatment of Parkinson's disease. Neurology. 2004; 63:S2-6.
31. Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol. 2006; 147:S287-96.
32. Holbrook AM, Pereira JA, Labiris R et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165:1095-106.
33. Chung L, Chakravarty EF, Kearns P et al. Bleeding complications in patients on celecoxib and warfarin. J Clin Pharm Ther. 2005; 30:471-7.
34. Jankel CA, McMillan JA, Martin BC. Effect of drug interactions on outcomes of patients receiving warfarin or theophylline. Am J Health-Syst Pharm. 1994; 51:661-6.
35. Glassman PA, Simon B, Belperio P et al. Improving recognition of drug interactions benefits and barriers to using automated drug alerts. Med Care. 2002; 40:1161-71.
36. Payne TH. Computer decision support systems. Chest. 2000; 118:47S-52S.
37. Silkey B, Preskorn SH, Golbeck A et al. Complexity of medication use in the Veterans Affairs healthcare system: part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract. 2005; 11:16-26.
38. Peterson JF, Bates DW. Preventable medication errors: identifying and eliminating serious drug interactions. J Am Pharm Assoc. 2001; 41:159-60.
39. Bates DW, Leape LL, Cullen DJ et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998; 280:1311-6.
40. Chen Y, Avery AJ, Neil KE et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf. 2005; 28:67-80.
41. Rollason V, Vogt N. Reduction of poly-pharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging. 2003; 20:817-32.
42. Bates DW, Cullen DJ, Laird N et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA. 1995; 274:29-34.
43. Hansten PD. Drug interaction management. Pharm World Sci. 2003; 25:94-7.
44. Van Roon EN, Flikweert S, Le Comte M et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf. 2005; 28:1131-9.